Viyash Scientific Q4 FY26 Results: PAT Rs 66 Cr

Viyash Scientific Q4 FY26 results were declared on May 19, 2026. Viyash Scientific reported PAT of Rs 66 crore up 560.0% YoY, on revenue of Rs 920 crore for the quarter ended March 31, 2026. Viyash Scientific is a Diagnostics and Healthcare company listed on Indian stock exchanges. This article covers the complete Viyash Scientific Q4 FY26 financial highlights, key performance factors, and FY27 outlook for investors tracking Viyash Scientific.

Click Here – Get Free Investment Predictions

Viyash Scientific Q4 FY26 Financial Highlights

Metric	Q4 FY26	Notes
PAT	Rs 66 crore	up 560.0% YoY
Revenue	Rs 920 crore	for the quarter ended March 31, 2026

Note: Q4 FY26 PAT Rs 66 crore (+560% YoY) on revenue Rs 920 crore. Strong diagnostic network expansion.

Viyash Scientific Q4 FY26 Performance Analysis

The Viyash Scientific Q4 FY26 results reflect Viyash Scientific’s operational performance during the January to March 2026 quarter. The company operates in the Diagnostics and Healthcare space, a sector supported by India’s strong GDP growth and domestic demand. The Q4 FY26 results demonstrate continued business execution and operational resilience.

Screen the best stocks on the Univest Screener.

Investors tracking Viyash Scientific Q4 FY26 will focus on FY27 revenue guidance, margin trajectory, and management’s capital allocation commentary. Track Viyash Scientific on the Univest Screener for live fundamentals and real-time updates.

Key Business Factors for Viyash Scientific Q4 FY26

Revenue and Operational Performance

The firm’s performance reflects the January to March 2026 quarter, historically the year-end quarter with strong order execution and seasonality effects. India’s macroeconomic environment with GDP growth above 6.5% provided a constructive backdrop for the Diagnostics and Healthcare sector during this period.

Profitability and Margin Trends

The company’s PAT of Rs 66 crore up 560.0% YoY. Sustaining profitability and improving operating margins will be key watchpoints for FY27 performance.

India Economic Context for Viyash Scientific

The January to March 2026 quarter saw strong domestic consumption, fiscal year-end capital expenditure cycles, and government infrastructure spending. The Reserve Bank of India’s supportive monetary stance and India’s resilient growth trajectory provided a stable environment for listed companies across sectors. For Viyash Scientific, operating in the Diagnostics and Healthcare space, this macro backdrop supported demand conditions during the quarter.

FY27 Outlook and Growth Drivers

Following the listed company results, management commentary on FY27 revenue guidance, capex plans, and order pipeline will be the primary catalysts for investor sentiment. The Diagnostics and Healthcare sector continues to benefit from India’s structural growth, rising domestic consumption, and government policy support.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the group

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.